When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
A 20-subject Phase 3 clinical trial, CMS-001, evaluating Catalyst Pharmaceuticals' (NASDAQ:CPRX) Firdapse (amifampridine phosphate) in patients at least two years old with symptomatic genetically confirmed congenital myasthenic syndromes (CMS), a group of conditions characterized by muscle weakness, failed to achieve the primary endpoint.
More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,